Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Rufinamide in Refractory Partial Seizures
2016-004950-14Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rufinamide in Focal Onset Epilepsy and epilepsy, sponsored by Eisai Co., Ltd. Primary endpoint: Percentage change in total partial seizure frequency.
02
Drugs
rufinamide
03
Conditions
Focal Onset Epilepsyepilepsy
Beyond the preview
Go deeper on 2016-004950-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004950-14.